The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Medical Dialogues11h
Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
High Growth Tech Stocks in Europe to Watch This March 2025
Amidst a backdrop of global trade policy uncertainty and mixed economic signals, the European market has shown resilience, with Germany's DAX Index rising by over 2% despite broader concerns impacting ...
Devdiscourse22h
A Global Health System at a Crossroads: Innovations, Challenges, and Leadership Changes
Current health news highlights include Apollo Hospitals' AI investments to alleviate staff workload, Dr. Mehmet Oz's Medicare ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
The Dow drops almost 500 points and the S&P enters a correction as Trump tariffs rattle investors again
Stocks entered a correction on Thursday as the S&P 500 index fell 10% from its recent peak after President Donald Trump escalated the trade war with 200% tariffs on European alcoholic beverages. This ...